BRIEF-Orangekloud Technology- Currently Estimated That Initial Public Offering Price Per Class A Ordinary Share Will Be Between $4.75 And $5.25-February 2024-www.financetom.com

BRIEF-Orangekloud Technology- Currently Estimated That Initial Public Offering Price Per Class A Ordinary Share Will Be Between $4.75 And $5.25

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Orangekloud Technology- Currently Estimated That Initial Public Offering Price Per Class A Ordinary Share Will Be Between $4.75 And $5.25

Jul 1, 2024 3:31 PM

July 1 (Reuters) -

* ORANGEKLOUD TECHNOLOGY- CURRENTLY ESTIMATED THAT INITIAL

PUBLIC

OFFERING PRICE PER CLASS A ORDINARY SHARE WILL BE BETWEEN $4.75

AND $5.25

Source text for Eikon:

Further company coverage: [ ]

Previous page： Factbox-JPMorgan leaders shaping its strategy as succession comes into focus Next page： PureTech Health Opens $100 Million Buyback Program

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Factbox-JPMorgan leaders shaping its strategy as succession comes into focus

May 20, 2024

(Reuters) - At JPMorgan Chase's ( JPM ) investor day on Monday, shareholders will focus on the bank's growth strategy and succession plans. CEO Jamie Dimon and President Daniel Pinto are among the key executives expected to be present. Dimon has run the largest U.S. lender for more than 18 years, and his next steps have been the subject of...

PureTech Health Opens $100 Million Buyback Program

May 20, 2024

06:35 AM EDT, 05/20/2024 (MT Newswires) -- PureTech Health ( PRTC ) said Monday it has opened a proposed tender offer to buy up to $100 million of ordinary shares of one pence each including its American Depositary Shares each representing 10 ordinary shares. PureTech Health ( PRTC ) offers to buy up to 33.5 million ordinary shares, which represents...

BRIEF-Cyberark Said To Near Deal To Buy Venafi, Deal Could Value Venafi At About $1.5 Billion- Bloomberg News

May 20, 2024

May 20 (Reuters) - * CYBERARK SAID TO NEAR DEAL TO BUY VENAFI; DEAL COULD VALUE VENAFI AT ABOUT $1.5 BILLION- BLOOMBERG NEWS Source text: https://tinyurl.com/5n8zbm88 ...

Shah Capital withdraws campaign against Novavax directors after Sanofi deal

May 20, 2024

May 20 (Reuters) - Hedge fund Shah Capital said on Monday that it was withdrawing its campaign against the re-election of three directors on Novavax's ( NVAX ) board, days after the COVID-19 vaccine maker struck a licensing deal with French drugmaker Sanofi. Shah Capital, which owns an about 7.8% stake in Novavax ( NVAX ), said that the agreement...